Abstract
INTRODUCTION
Alzheimer’s disease (AD) initiates years prior to symptoms, underscoring the importance of early detection. While amyloid accumulation starts early, individuals with substantial amyloid burden may remain cognitively normal, implying that amyloid alone is not sufficient for early risk assessment.
METHODS
Given the genetic susceptibility of AD, a multi-factorial pseudotime approach was proposed to integrate amyloid imaging and genotype data for estimating a risk score. Validation involved association with cognitive decline and survival analysis across risk-stratified groups, focusing on patients with mild cognitive impairment (MCI).
RESULTS
Our risk score outperformed amyloid composite standardized uptake value ratio in correlation with cognitive scores. MCI subjects with lower pseudotime risk score showed substantial delayed onset of AD and slower cognitive decline. Moreover, pseudotime risk score demonstrated strong capability in risk stratification within traditionally defined subgroups such as early MCI, apolipoprotein E (APOE) ε4+ MCI, APOE ε4– MCI, and amyloid+ MCI.
DISCUSSION
Our risk score holds great potential to improve the precision of early risk assessment.
Highlights
Accurate early risk assessment is critical for the success of clinical trials.
A new risk score was built from integrating amyloid imaging and genetic data.
Our risk score demonstrated improved capability in early risk stratification.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Bing He,
Ruiming Wu,
Neel Sangani,
Pradeep Varathan Pugalenthi,
Alice Patania,
Shannon L. Risacher,
Kwangsik Nho,
Liana G. Apostolova,
Li Shen,
Andrew J. Saykin,
Jingwen Yan,
for the Alzheimer’s Disease Neuroimaging Initiative | September 17, 2024